Reply - setting the record straight on setting the record straight: response to the Light and Warburton rejoinder
Article Abstract:
The critical review by Donald W. Light and Rebecca N. Warburton of a study relating to quality of data and sampling used for arriving at the costs of pharmaceuticals Research and Development is discussed and clarifications in respect thereto are presented.
Publication Name: Journal of Health Economics
Subject: Health care industry
ISSN: 0167-6296
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Anti-social welfare functions: a reply to Hasen et al
Article Abstract:
The discrepancies in analysing the relationship between cost benefit analysis (CBA) and cost effectiveness analysis (CEA) are presented. The use of social welfare function and assumptions of welfarist framework are questioned.
Publication Name: Journal of Health Economics
Subject: Health care industry
ISSN: 0167-6296
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
On the possibility of a bridge between CBA and CEA: comments on paper by Dolan and Edlin
Article Abstract:
The relation between cost benefit analysis (CBA) and cost effectiveness analysis(CEA) is established which is in contradiction to study conducted by Dolen and Edlin.
Publication Name: Journal of Health Economics
Subject: Health care industry
ISSN: 0167-6296
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism
- Abstracts: Early occurrence of aortic valve regurgitation in a youth with systemic-onset juvenile rheumatoid arthritis. Prognostic significance of valvular regurgitation in patients with infective endocarditis
- Abstracts: Telling the public the real health cost story. Moving from competition to collaboration. Taking environmental action: what you can do
- Abstracts: Urine drug screening: understanding the process, understanding the limitations. Emerging ethical issues in pharmacogenomics: from research to clinical practice
- Abstracts: Key industry ratios and statistics. part 5